When the Barrel Turns, Your Portfolio Should Pivot With It

Energy’s catching a tailwind, software is pricing the holidays, fintech is building an ad network, and utilities are quietly cutting deals with the data-center crowd.

Here’s the fastest way to turn headlines into a plan.

Year-End Winners (Sponsored)

The 5 Picks You’ll Want Before Year-End

What if your next trade could double your money by next year?

Inside our new 5 Stocks Set to Double report, you’ll discover companies showing powerful growth signals — the kind that often precede triple-digit runs.

Past editions have revealed opportunities that went on to gain +175%, +498%, even +673%.¹

Get your free copy now before this special access expires at MIDNIGHT TONIGHT.

[Download the report for free now.]

*This free resource is being sent by Zacks. We identify investment resources you may choose to use in making your own decisions. Use of this resource is subject to the Zacks Terms of Service.
*Past performance is no guarantee of future results. Investing involves risk. This material does not constitute investment, legal, accounting, or tax advice. Zacks Investment Research is not a licensed dealer, broker, or investment adviser.

Never Miss a Stock Alert Again!

We now send our daily picks via SMS too — so you’ll get the same high-conviction ideas, even if you miss the email.

👉 Click here to get stock picks by text and stay in the loop, always.

Vertex Pharmaceuticals | VRTX

Price: $410.12

Nothing flashy this week, but the setup is constructive. Vertex reports Nov 3 and sits on one of biotech’s rarest assets: durable, high-margin franchises funding a broad pipeline.

Cystic fibrosis cash keeps the lights bright while newer launches in hemoglobinopathies and pain diversify the story.

Street debates valuation near the high end for large-cap biotech, yet cash flow plus late-stage shots on goal often deserve premium multiples, especially when execution is consistent.

Here you can accumulate on red days ahead of earnings if you’re underweight healthcare growth.

Focus on three tells, the revenue durability in CF beyond 2030, early adoption curves in sickle cell and TDT, and clarity on readouts in kidney disease and pain.

Maintain a partial hedge if you’re sizing up, since single-drug readouts can move the tape.

Why it matters to you: VRTX is one of the few biotech names where operating leverage and pipeline breadth lower downside while preserving upside torque.

American Express | AXP

Price: $327.91

Amex just rolled out Amex Ads, a first-party ad platform starting on AmexTravel.com that lets brands target high-spend cardmembers at intent-rich moments.

It leans on a core advantage, closed-loop data, and could create a flywheel: more advertisers, more relevant offers, more spend, more fees. 

Meanwhile, travel and premium consumer activity have stayed surprisingly resilient, keeping loan growth and fee income in decent shape.

AXP’s risk lives in credit normalization and global macro wobbles, but the balance sheet and underwriting history buy time.

You can buy pullbacks tied to rate jitters or credit headlines; trim rips when yields fall and everything financial rallies.

Track billed business growth, net write-offs in consumer and small-business cards, and early monetization metrics from Amex Ads.

If operating leverage improves while delinquencies stay orderly, multiple expansion can follow.

Why it matters to you: you’re getting a profitable payments franchise, a durable brand, and a new data-driven revenue stream, without paying software-style multiples.

Last Window Open (Sponsored)

7 Stocks Ready to Run Before the Year Ends

The clock is ticking — 2025’s final quarter could be the last big rally before the 2026 reset.

We’re seeing clear market signals:

• Rate cuts ahead

• Energy shocks disrupting supply chains

• AI and defense spending hitting new highs

Our team has identified 7 stocks perfectly positioned to benefit from this volatile mix.

This is your chance to end 2025 strong — before Wall Street drives these prices higher.

Claim your free “Top 7 Stocks for Q4 2025” report now.

When the year closes, you’ll either wish you acted — or be glad you did.

Adobe | ADBE

Price: $348.19

The stock has been re-rated lower in 2025, but Adobe just forecast another record online holiday with more than $250B in U.S. spend and a bigger role for mobile, BNPL, and AI-assisted shopping.

That matters because Experience Cloud is tied to those flows, and Firefly/Creative Cloud can monetize the creator wave powering holiday marketing. 

Investors want proof of net new ARR acceleration and margin stability to believe the reset is behind us.

If management shows that gen-AI features drive higher seat retention and ARPU, the narrative can turn.

Build a starter position here for the quality bucket; add on confirmation of ARR cadence and generative-AI attach in Q4 remarks.

Watch Experience Cloud bookings, Creative seat churn, and guidance for FY26 operating margins.

If shares reclaim key moving averages on improving ARR, a grind back toward historical multiples is on the table.

Why it matters to you: Adobe remains mission-critical for content and commerce. If AI becomes an upsell rather than a giveaway, earnings power is still underappreciated.

NextEra Energy | NEE

Price: $83.23

Coverage is heating up again. Fresh analyst initiations highlight NextEra’s dominant renewables platform plus the regulated backbone of Florida Power & Light.

The new angle for 2026 and beyond is long-term power deals with hyperscalers that want clean, reliable juice for data centers. 

Pair that with nuclear life-extensions and selective gas capacity, and you get a utility that can look like a growth stock in slow-motion.

Risks remain, like rates, permitting, supply chain, but the balance sheet and development machine are best-in-class.

You’ll want to buy on rate-spike days when bond yields pressure utilities.

Track contracted backlog growth, cost of capital versus ROE in rate cases, and any hyperscaler PPA headlines.

If management holds the EPS CAGR guide and keeps leverage in check, dividend growth stays intact and the multiple has room to breathe.

Why it matters to you: NEE blends defense (regulated cash flows) with offense (renewables pipeline). It’s a way to play the AI power buildout without owning the server racks.

Exxon Mobil | XOM

Price: $114.26

Exxon just guided to a sizable Q3 uplift from commodity tailwinds.

Management flagged a potential earnings boost from crude and gas price moves, plus another lift from refining margins, partially offset by restructuring costs. 

This means integrated scale is doing its job, and downstream is carrying more weight while upstream rides price.

With a dividend near the mid-3s and a sub-market beta, XOM remains one of the cleaner ways to own oil without whiplash.

The game plan here is to buy weakness into results and scale up if crack spreads hold post-print.

Watch realized liquids pricing, downstream margins, and cash allocation between shareholder returns and low-carbon projects like carbon capture.

If Brent stays firm and chemicals recover, free cash flow should hand you both a dividend raise and continued buybacks.

Why it matters to you: if you want cyclical exposure that still pays you to wait, a disciplined integrated major with a stout balance sheet is hard to beat.

Stat of the Day: $1 Trillion

AMD’s OpenAI deal just lit a path where hitting $600 per share would imply a trillion-dollar market cap.

The bigger takeaway is that inference demand is exploding, and second-sources to Nvidia will matter.

Keep a sleeve in your portfolio for the AI supply chain beyond the headline leader, power, cooling, networking, accelerators, and the utilities feeding the grid.